Details of the Drug Combination

General Information of Drug Combination (ID: DCXI9F0)

Drug Combination Name
JQ1 Ombrabulin
Indication
Disease Entry Status REF
Ewing sarcoma Investigative [1]
Component Drugs JQ1   DM3XQDH Ombrabulin   DM25HY3
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: TC-71
Zero Interaction Potency (ZIP) Score: 13.297
Bliss Independence Score: 14.392
Loewe Additivity Score: 1.526
LHighest Single Agent (HSA) Score: 5.03

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of JQ1
Disease Entry ICD 11 Status REF
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [2]
JQ1 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
HUMAN bromodomain-containing protein 2 (BRD2) TTNISW6 BRD2_HUMAN Inhibitor [2]
------------------------------------------------------------------------------------
Indication(s) of Ombrabulin
Disease Entry ICD 11 Status REF
Sarcoma 2A60-2C35 Phase 3 [3]

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Uncovering the Role of BRD2 in COVID-19. 2020-03-19
3 ClinicalTrials.gov (NCT00699517) A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies. U.S. National Institutes of Health.